弗莱卡尼德毒性 - - 临床诊断和紧急情况的管理
George Bazoukis1,2, Polyxeni Efthymiou1, Andronicos Yiannikourides1
1Department of Cardiology Larnaca General Hospital Larnaca Cyprus.
Clinical case reports
|September 2, 2024
概括
诊断弗莱卡尼德毒性涉及临床症状和心电图. 管理策略包括二碳酸,脂质乳液和体外生命支持,用阿米奥达龙或利多卡因治疗稳定的心跳动.
科学领域:
- 心脏病学 心脏病学
- 临床毒理学 临床毒理学
背景情况:
- 弗莱卡尼德是一种抗心律失常药物,具有狭窄的治疗指数.
- 毒性可能导致严重的心血管并发症.
研究的目的:
- 对弗莱卡因毒性的诊断方法进行审查.
- 总结目前对飞胺毒性的管理策略.
- 讨论在弗莱卡因毒性中管理心律失常的治疗选择.
主要方法:
- 对弗莱卡尼德毒性诊断标准的文献综述.
- 分析报告的管理策略,包括药理和非药理干预措施.
- 对与广泛QRS复杂性心率障碍相关的抗心律失常疗法的综述.
主要成果:
- 临床怀疑,呈现和心电图的发现是关键的诊断工具.
- 对于弗莱卡尼德的毒性管理,目前还没有确定的指导方针.
- 使用的治疗方法包括二碳酸,脂质乳液和体外生命支持.
- 阿米奥达龙和利多卡因是患有广泛QRS复杂性心动减速症的稳定患者的选择.
结论:
- 早期诊断弗莱卡因毒性的依赖于临床评估和心电图.
- 管理层在很大程度上是支持性的,并以案例报告和专家意见为指导.
- 具体的抗心律失常选择取决于血液动力学稳定性和心电图的发现.
相关概念视频
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
1.3K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.3K
Heart Failure Drugs: Inotropic Agents
545
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
545
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
935
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
935
Flail Chest-II
160
Managing flail chest, a condition characterized by a segment of the chest wall moving independently from the rest of the thoracic cage, requires a comprehensive approach. It includes a thorough assessment of the patient's condition, a diagnostic evaluation to determine the extent of the injury, and the implementation of appropriate medical interventions tailored to the individual's needs.
Assessment:
1. Clinical Evaluation:
History:
Assessment:
1. Clinical Evaluation:
History:
160
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
719
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
719
Renal Failure: Dose Adjustments
69
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
69


